Regenesis Biomedical, a medical device company focused on safe, non-drug, pain management, announced U.S. Food and Drug Administration (FDA) clearance of the Reprieve by Regenesis device (Reprieve).
Reprieve is a home-use shortwave diathermy device based on Regenesis’ core pulsed electromagnetic energy platform.
“In alignment with our Vision to improve health for a longer, more active, and fulfilling life, we are pleased to announce we received Food and Drug Administration clearance for our new Reprieve by Regenesis device,” said Tom Eisiminger, president and CEO.
Regenesis is a privately held medical device company that makes energy-based medical products and services that alleviate pain, restore health, and improve quality of life. The company focuses on serving the needs of Veterans through its direct salesforce. Over 23,000 patients have been treated with Regenesis non-drug, electromagnetic energy for pain management.
“Reprieve allows us to market our therapy for broad pain indications within the Department of Veterans Health Administration (VA), which represents a market that is 16X the size of our current market,” said Eisiminger. “Because our new device has a two-treatment applicator option, we are expanding our efforts into the podiatric space with a focus on the treatment of pain associated with diabetic neuropathy.”
Photo courtesy of Regenesis
